Showing 1 to 13 of 13 trials. Show trials.
Print List Download
 
Trial Name Trial ID Main Coordinating Centre
and contact		 Status Recruitment Topic Participants Details
CIRCA DIEM ACTRN12618000371291p Jane Pillow
+61417621960
jane.pillow@uwa.edu.au
The University of Western Australia		 Not yet recruiting
IMPACT endorsed
 Newborn – developmental
 Babies born at < 31 weeks and 6 days postmenstrual age. Have initial care at a perinatal centre where routine care does not include individual environmental light/noise cycling.
DIAMOND - DIfferent Approaches to MOderate & later preterm Nutrition: Determinants of feed tolerance, body composition and development ACTRN12616001199404 Liggins Institute, University of Auckland
t.alexander@auckland.ac.nz		 Currently recruiting
IMPACT endorsed
 Newborn nutrition Newborn body composition Neurodevelopment Preterm babies between 32+0 - 35+6 admitted to the neonatal unit requiring IV insertion
EPPI Trial - Enoxaparin for the Prevention of Preeclampsia and Intrauterine growth restriction ? a pilot randomised placebo-controlled trial ACTRN12609000699268 Department of Obstetrics and Gynaecology, University of Auckland. Laura Mackay (Trial Manager) laura.mackay@auckland.ac.nz; Dr Katie Groom (Chief Investigator) k.groom@auckland.ac.nz Recruitment complete
IMPACT reviewed
 Fetal growth. Preeclampsia Women with previous pregnancy complicated by early onset preeclampsia or fetal growth restriction
LIFT - Lactoferrin Infant Feeding Trial to prevent sepsis and death in preterm infants ACTRN12611000247976 NHMRC Clinical Trial Centre, NSW

lift@ctc.usyd.edu.au		 Currently recruiting
IMPACT reviewed
MAGENTA - Does antenatal magnesium sulphate given to women at risk of preterm birth between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children? - a randomised controlled trial. ACTRN126110000491965 University of Adelaide, Clinical Trial Manager Pat Ashwood +61 8 8161 7767
 Currently recruiting
IMPACT reviewed
 Neuroprotection, Antenatal magnesium sulphate, Cerebral palsy
 Women at risk of preterm birth between 30 and 34 weeks’ gestation where birth is planned or definitely expected within 24 hours, have a singleton or twin pregnancy, no contraindications to the use of antenatal magnesium sulphate
MBM - My Baby’s Movements: a stepped wedge cluster randomised controlled trial to raise maternal awareness of fetal movements during pregnancy ACTRN12614000291684 Mater Research Institute - The University of Queensland u.chandrasiri@mater.uq.edu.au Not yet recruiting
IMPACT endorsed
 Stillbirth prevention. Fetal surveillance. Parental social and emotional wellbeing. Pregnant women without any congenital abnormalities
N3RO - Can omega 3 fatty acids improve respiratory outcomes in preterm infants? ACTRN12612000503820 Women's & Children's Health Research Institute carmel.collins@health.sa.gov.au Recruitment complete
IMPACT reviewed
 Newborn respiratory Born at less than 29 weeks gestational age, within 3 days of commencing enteral feeds
PAEAN - Preventing Adverse Outcomes of Neonatal Hypoxic Ischaemic Encephalopathy with Erythropoietin: a randomised placebo controlled multicentre clinical trial ACTRN12614000669695 NHMRC Clinical Trials Centre, University of Sydney

paean@ctc.usyd.edu.au

+61 2 9562 5000

 Currently recruiting
IMPACT reviewed
 Newborn – developmental
POP-OUT - Persistent Occiput Posterior: OUTcomes following manual rotation ACTRN12612001312831 Royal Prince Alfred Hospital, NSW hala.phipps@email.cs.nsw.gov.au Recruitment complete
IMPACT reviewed
 Labour and intrapartum care
PROTECT - Can Pentoxifylline improve long-term outcomes in preterm infants with late-onset sepsis or necrotizing enterocolitis? A pragmatic, randomized, controlled trial ACTRN12616000405415 NHMRC Clinical Trial Centre, NSW
protect@ctc.usyd.edu.au

 Currently recruiting
IMPACT reviewed
 Preterm infant sepsis and inflammation, neurodevelopment Born at less than 29 weeks gestational age with suspected late-onset sepsis or necrotizing enterocolitis
PROVIDE - Impact of Protein IVN on Development: for extremely low birthweight babies, does higher intravenous protein intake in the first 5 days after birth improve neurodevelopmental outcome, growth and body composition through to 2 years of age? ACTRN12612001084875 Liggins Institute, University of Auckland, Barbara Cormack bcormack@adhb.govt.nz Currently recruiting
IMPACT reviewed
 Protein, intravenous nutrition, neurodevelopment Birthweight <1000 g
STRIDER (NZAus)- A randomised placebo-controlled trial of a new therapy (sildenafil) to help growth in severely growth restricted fetuses at very early gestations ACTRN12612000584831 Department of Obstetrics and Gynaecology, University of Auckland Laura Mackay (Trial Manager) laura.mackay@auckland.ac.nz; Dr Katie Groom (Chief Investigator) k.groom@auckland.ac.nz Recruitment complete
IMPACT reviewed
 Fetal growth. Preeclampsia. Pterterm birth - prevention and treatment Women with pregnancies complicated early onset fetal growth restriction. Abdominal circumference ≤3rd centile at 22-28 weeks or EFW <700g at 28-80 weeks
The PROTECT Me trial RES-17-0000-583A Monash Medical Centre Clayton
Dr Kirsten Palmer
kirsten.palmer@monash.edu		 Currently recruiting
IMPACT endorsed
 Early onset Intrauterine Fetal Growth Restriction Women with pregnancies complicated by severe fetal growth restriction between 23+0 and 31+6 weeks gestation